BioStock: Curasight CEO comments on capital raise and milestone

Curasight has enrolled the first patient in its phase II trial with uTRACE in prostate cancer, activating a second USD 500,000 payment from partner Curium. Curasight also announced a capital raise aimed at further strengthening the company’s finances. The fund raise, which includes a directed share issue, a loan facility, and warrants will initially provide DKK 27.8 million, and the package could eventually provide up to DKK 120 million.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/06/curasight-ceo-comments-on-capital-raise-and-milestone/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se